Great pick up!
And logic would entail if the SubB2M Prostate & Pancreatic results are also excellent like the Breast/Ovarian results, then I have confidence Bard1 will continue to expand the SubB2M technology across all main cancers. Lung etc.
SubB2M may be able to efficiently detect all types of cancer. If it can detect Breast & Ovarian will 100& or 95% accuracy then there is definitely a good chance it will be able to detect most types of cancer.
The upside here is ginormous, how are we still at sub $500m market cap.
Pending testing results, page-216
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.020(3.39%) |
Mkt cap ! $67.26M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 61.0¢ | 58.0¢ | $56.05K | 95.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2999 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 12999 | 3 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |